Recruiting now

Study of Lunsekimig Compared With Placebo in Adult Participants With COPD

Enrolling at: Windsor
Phase 3Study phase
≈11 monthsStudy length
40–80Age range
1 siteResearch locations

About this study

Are you struggling with managing symptoms of Chronic Obstructive Pulmonary Disease (COPD)?

This is a Phase 2/3 study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype.

Participation to the study consists of 3 periods:

  • Screening period of up to 4 weeks
  • Randomized intervention period of approximately 48 weeks
  • Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.

Would you like to take part?

As a volunteer in a research study, you’ll receive study-related medical care from the study doctor and regular follow-up of your health to monitor the effectiveness of the care you’ll receive. The results of this research will be used to find out if the investigational medication being studied will be of benefit to others struggling with COPD, and whether it will be made widely available to all Canadians trying to manage this condition. Study volunteers are an important part of moving medical care forward.

Who may qualify

You may qualify if
  • Are between 40 to 80 years of age, inclusive
  • Have physician diagnosed chronic obstructive pulmonary disease (COPD) for ≥1 year
  • Have post-bronchodilator forced expiratory volume in 1 second (post-BD FEV1) ≥ 20% and ≤ 70% of predicted value and FEV1/FVC (forced expiratory volume in 1 second /forced vital capacity) <0.70
  • Are a former or current smoker with ≥10 pack-years
  • Record a Chronic Airways Assessment Test (CAAT) of ≥10
  • Have had ≥2 moderate or ≥1 severe COPD exacerbations in the prior year
  • Have been using triple (ICS+LABA+LAMA) COPD therapy ≥12 consecutive weeks
  • Test for EOS (blood eosinophil count) ≥ 150 cells/μL
  • Have a 18.0 ≤ Body Mass Index ≤ 40.0 kg/m2
This study may not be a fit if
  • Have asthma, including pediatric asthma, or ACOS
  • Have any significant pulmonary disease other than COPD
  • Require long-term oxygen therapy >4.0 L/min or requirement of >2.0 L/minO2 saturation to maintain oxygen saturation >88%
  • Have any unstable disorder that can impact participants safety or study outcomes
  • Have active or incompletely treated tuberculosis
  • Have any current or past malignancies
  • Take any concomitant therapies:
    • long-term macrolides or iPDE-4 unless on stable therapy for > 6 months
    • any biologic therapy or systemic immunosuppressant within 8 weeks or 5 half-lives prior to Screening
Every study has additional criteria the research site will review with you.

What participation may involve

  • Regular visits with the study team at no cost
  • Study assessments and health monitoring throughout
  • Check-ins between visits
  • Informed consent before anything begins — questions welcome
Time commitment: ≈11 months — confirmed by the research site. The full visit schedule is explained during informed consent.

What participants may receive

  • Study-related care from a physician-led team
  • Study assessments at no cost
  • Reimbursement for reasonable travel, where applicable
Specifics vary by study and site, and are never a guarantee of benefit. Being in a study is not a substitute for regular medical care.
Participating research sites

Where this study is enrolling

WINDSOR, ONWindsor Health CentrePrincipal investigator: Dr. Syed Anees, Dr. Sabeen AnwarView site →

Learn more

About the condition

Chronic Obstructive Pulmonary Disease (COPD)

Chronic obstructive pulmonary disease, or COPD, is a long-term lung condition in which the airways are narrowed and the small air sacs deep in the lungs are damaged.…

Read about this condition →
Related reading
Chronic Obstructive Pulmonary Disease (COPD)FDA Approves Nucala for COPD Patients with High Eosinophil LevelsRead →AsthmaAstraZeneca Advances Breztri Inhaler for Asthma TreatmentRead →Chronic Obstructive Pulmonary Disease (COPD)COPD Signs and Symptoms Plus When To See A DoctorRead →

Other studies you can explore

All current studies →
RecruitingStudy for Patients With Idiopathic Pulmonary Fibrosis (IPF)WindsorCheck availability →RecruitingStudy in People With Moderate to Severe Chronic Obstructive Pulmonary DiseaseWindsorCheck availability →RecruitingStudy of Initiating DepemokImab Early Therapy in Chronic Obstructive Pulmonary Disorder (COPD)WindsorCheck availability →

Common questions

Do I have to decide now?
No. Answering the questions is not a commitment — it simply lets the research team see whether this study may be appropriate and contact you to talk it through.
Will it cost me anything?
No. Study visits and study assessments are provided at no cost, and reasonable travel may be reimbursed where applicable.
What happens after I submit the form?
A member of the research team reviews your answers and contacts you — usually within two business days — to answer questions and review the next steps.
Could I receive a placebo?
Some studies compare a treatment with a placebo. Whether this study does is explained clearly during informed consent, before you decide anything.
Can I leave the study after it starts?
Yes. Participation is always voluntary. You can withdraw at any time without giving a reason and without it affecting your regular medical care.
Request contact

Ask the research site to contact you

Your answers go to our research team and the study site, help the team prepare before they call — and completing the form doesn’t obligate you to take part.
Study interest form

See if you may qualify

A few quick questions — about a minute. Your answers help the research team prepare before they contact you.

For anyone under 18, a parent or legal guardian should complete this form and would need to consent on their behalf.

See if you may qualify →